Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks
- ResMed, Inspire Medical, AdaptHealth tumble after data
- Analysts see GLP-1 drugs disrupting sleeping-device sector
This article is for subscribers only.
The new class of weight-loss drugs being tested as cure-alls for everything from knee replacements to liver disease keeps throwing corners of the stock market into disarray.
Late Friday, data for tirzepatide — the chemical compound Eli Lilly & Co. sells as Mounjaro and Zepbound — shook markets once again as makers of machines for sleep-related disorders tumbled. The data showed Lilly’s blockbuster weight loss and diabetes medicine reduced the severity of obstructive sleep apnea in obese patients.